J. C. de la Torre

This study evaluates 19 compounds for antiviral activity against Orthopoxviruses, identifying 13 with activity against vaccinia virus and 11 with activity against monkeypox virus.

The paper identifies eRF3a/GSPT1 as a druggable host target for antiviral therapy against Lassa virus by analyzing its interactome using proximity proteomics.

This paper shows Bcl-2 inhibitors like ABT-737 and OLX block mammarenavirus and SARS-CoV-2 by causing G0/G1 cell cycle arrest, not through apoptosis.

The paper identifies functional interactors of the Ebola virus polymerase using proximity proteomics and validates their role in promoting viral replication.

The paper develops a TR-FRET assay for SARS-CoV-2 NP detection, enabling high-throughput screening of compounds against SARS-CoV-2 and its variants.

This paper develops a bifluorescent-based assay to identify neutralizing antibodies against SARS-CoV-2 variants in vitro and in vivo, showing it accurately reflects viral neutralization.

This study develops a method to visualize SARS-CoV-2 infection dynamics using reporter-expressing recombinant viruses, enabling real-time tracking and antibody screening in vivo.

This paper develops a high-throughput AlphaLISA assay to detect SARS-CoV-2 nucleocapsid protein, enabling screening of antiviral compounds.

The paper develops an infectious SARS-CoV-2 cDNA clone using a bacterial artificial chromosome, which replicates similarly to the natural virus in cell cultures and animal models.